TAmiRNA seeks to identify and characterize small non-coding RNA molecules referred to as “microRNAs”, which contribute to the process of aging or the development of age-related diseases. Ultimately, TAmiRNA uses this knowhow to develop novel medical applications of microRNAs as diagnostic tests or therapeutic drugs to enable personalized treatment of disease.
R&D:Novel, minimal-invasive in-vitro diagnostic tests are developed in the following areas: musculoskeletal, cardiovascular and metabolic diseases.
Services:TAmiRNA offers services for RNA biomarker discovery, validation and commercialization.
Muthgasse 18
1190 Vienna
Vienna
Contact: Matthias Hackl (CEO)
Telephone: +43 (699) 10709-41
Email: office@tamirna.com
Website